The Hemopurifier is a medical device that assists the immune response in combating infectious disease through real-time therapeutic filtration of infectious viruses and immunosuppressive proteins.
As in previous studies, which demonstrated robust viral load reductions resulting from three Hemopurifier treatments administered in a one-week trial, the study enrolled an hepatitis-C virus (HCV) patient suffering from end-stage renal disease (ESRD) requiring regular kidney dialysis treatment.
The study goal was to further demonstrate the Aethlon Hemopurifier inhibits the progression of HCV in infected ESRD patients. The study protocol provided for 12 Hemopurifier treatments to be administered during the patient’s normally scheduled dialysis treatment. As a result, a four-hour Hemopurifier treatment was administered thrice weekly over a period of 30 days. There were no observed adverse events were reported in any of the treatments. The study was conducted at the Fortis Hospital in Delhi, India.
According to Aethlon, the study data may be utilized to expand the scope of an investigational device exemption submission to the FDA to include the potential use of the Hemopurifier in the US as a device designed for the single-use removal of HCV from blood.
Jim Joyce, chairman and CEO of Aethlon, said: “The continued demonstration of Hemopurifier safety and effectiveness increases the likelihood that our technology will be available to extend and improve the lives of those suffering from these horrific conditions.”